Atea Pharmaceuticals (AVIR) vs DiaMedica Therapeutics (DMAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed DiaMedica Therapeutics (DMAC) over the past year, gaining 68.7% versus a gain of 16.5%. Over five years, DMAC leads with a +94.9% price change compared with -87.2% for AVIR. DiaMedica Therapeutics is the larger company by market cap ($430.9 million vs $401.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | DMAC |
|---|---|---|
| Share price | $5.01 | $7.99 |
| Market cap | $401.83M | $430.87M |
| 1-day change | -1.18% | -1.72% |
| YTD return | +40.34% | +0.38% |
| 1-year return | +68.69% | +16.47% |
| 5-year return | -87.25% | +94.88% |
| EPS (TTM) | $-2.07 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $10.42 |
| 52-week low | $2.87 | $5.25 |
| Distance from 52-week high | -22.33% | -23.32% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +88.02% | +93.99% |
| Average volume | 298.92K | 175.72K |
| Shares outstanding | 80.20M | 53.93M |
| Employees | 55 | 35 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed DMAC by 52.2 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Healthcare · Biotechnology · 55 employees
About DiaMedica Therapeutics
DMAC stock →DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction.
Healthcare · Biotechnology · 35 employees
AVIR vs DMAC FAQ
Which is bigger, Atea Pharmaceuticals or DiaMedica Therapeutics?
DiaMedica Therapeutics (DMAC) is larger, with a market capitalization of $430.87M compared with $401.83M for Atea Pharmaceuticals (AVIR).
Which stock has performed better over the past year, AVIR or DMAC?
AVIR returned +68.69% over the past 12 months, compared with +16.47% for DMAC (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and DiaMedica Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.